Lissencephaly

A Study of 133 Consecutive Cases

The surgical treatment of epilepsy is now an established mode of therapy in various clinical settings.1 Engel estimated that as of the early 1990s more than 8000 patients had undergone a surgical procedure as the definitive treatment for pharmacoresistant seizure disorder.2 As Engel emphasized, only a small fraction of surgical candidates are at present referred to epilepsy surgery centers, meaning that a huge treatment opportunity is being missed.

Until the 1990s, anterior temporal lobectomy, or amygdalohippocampectomy, accounted for more than two thirds of all surgical procedures used to treat epilepsy.2 Within the past 10 years, focal neocortical resections, 'lesionectomies,' and hemispherectomies have been used increasingly more often to treat intractable seizures in some of the patients most refractory to drug therapy, that is, infants and children with infantile spasms and intractable seizures that begin in the first years-often the first weeks-of life.3,4 This radical form of neurosurgical intervention has provided pathologists with unique and challenging tissue specimens, whose range was well described in an article by Frater et al,5 which appeared in the April issue of the ARCHIVES. Understanding the pathogenesis and prognosis of lesions within such specimens may tell us a great deal about the neurobiology of epileptogenesis.

Frater et al nicely summarize the variety of lesions encountered among many epilepsy surgery centers. The relative frequency of the different specimen types varied tremendously among centers adept at this complex form of surgical intervention, often depending on local expertise and interests. As with all studies of archival material, the pathologic specimens were obtained over a long period of time from patients who were operated on over a broad age range, from 3 months to 57 years. As one would expect, the material available for study from different resections was tremendously variable in amount and was probably examined using a variety of special and immunohistochemical stains.

Cortical dysplasia6 (CD) was noted to be the major neuropathologic abnormality in more than a third of cases. Neoplasms (usually of an indolent nature) were found in more than a quarter of patients, and evidence of 'remote' encephalomalacia was identified in less than a fifth. The etiology of these destructive lesions almost always remains obscure, even after they have been studied in great detail, but they are presumed (perhaps incorrectly) to represent sequelae of intrauterine or perinatal/neonatal ischemia in the brain. The developing central nervous system is vulnerable to a variety of vascular and hypoxic-ischemic insults, including periventricular white matter necrosis, germinal matrix hemorrhage, and venous thrombosis. The precise etiology of a given region of encephalomalacia may be impossible to discern when it is examined weeks, months, or years after the precipitating event.7-9 Furthermore, toxic and infectious processes may cause tissue destruction, which closely mimics that caused by vascular lesions.10 Small numbers of cases of vascular malformation, Sturge-Weber disease, and Rasmussen encephalitis were also found.5

Of interest, just less than 20% of specimens showed no discernible pathologic abnormality. As Frater et al appropriately surmise, the origin of seizures in these cases may be at a cellular or molecular level that has no obvious morphologic correlate. However, it is also possible that evaluation of the tissue using rigorous morphometric techniques might reveal structural abnormalities not apparent on routine light microscopic examination. Such methodologies are currently beyond the range of activities in most diagnostic pathology laboratories, although they are likely to play a major role in the future.11,12

The high incidence of malformative and destructive lesions studied by Frater et als reinforces the impression from pediatric epilepsy surgery centers that these structural changes (sometimes described as neuronal migration disorder (NMD]) most commonly account for intractable epilepsy (including infantile spasms/ West syndrome) in infants and children.13,17 The authors did not, unfortunately, substratify patients by the nature of their seizure disorder or by their age (at either presentation or surgery). It would also have been of interest to know how effective epilepsy surgery was in the context of each type of neuropathologic abnormality encountered (ie, in currently fashionable terminology, what was the outcome of surgical intervention in a malformative vs a destructive or neoplastic lesion).

While identifying morphologic abnormalities in extratemporal corticectomies from epileptic patients is both valuable and of importance for assessing prognosis, a note of caution is in order. An epilepsy-associated lesion, bizarre though it may appear (as in many cases of CD), might have little to do with the causes) of a given seizure disorder. Rather, it may simply represent a marker for underlying brain disease that is the proximate cause of epilepsy. Patients with tuberous sclerosis (TSC) may, for example, have several cortical tubers of similar morphologic appearance within the brain, yet only one of these may be epileptogenic.18 In CD / NMD, abnormalities of expression of neurotransmitters / neurotransmitter receptors on aberrant neurons may represent a 'molecular lesion,' which (rather than the structural lesion itself) predisposes to seizure genesis19-21

Cortical dysplasia is perhaps the most neurobiologically intriguing of the lesions described in the study by Frater et al, and in many other articles on extratemporal resections for seizure disorder as well. As the authors indicated, both the gross and microscopic morphologic appearances of CD can be remarkably variable, possibly reflecting the timing of the (presumed) intrauterine insult that resulted in anomalous neuronal migration to, or maturation within, the neocortex 6 In its most extreme form, CD may be associated with hemi-megalencephaly / hemi-lissencephaly.22 By light microscopy, severe CD is often associated with profound neuronal cytoskeletal abnormalities. Frater et al appropriately pointed out the possible linkage or continuum between CD / NMD and tumors that appear to have a glioneuronal malformative component, for example, gangliogliomas and dysembryoplastic neuroepithelial tumors.

Perhaps an even more intriguing etiologic connection exists between CD / NMD and TSC. Cortical tubers of TSC may give rise to epilepsy and morphologically show a striking resemblance to foci of severe CD, ineluding 'balloon cell change, neuronal cytomegaly and dysmorphism, and profound cytoskeletal abnormalities.6,18,24 Tuberous sclerosis-associated genes (TSC1, TSC2 ), mutations in which determine the TSC phenotype (including brain lesions), have recently been cloned.25,26 Both TSC1 and TSC2 transcripts and their encoded proteins, hamartin and tuberin, respectively, are widely and abundantly expressed in viscera and the developing and mature healthy central nervous system, as well as in TSC brain lesions.27-30 Precisely how they determine the formation of multifocal dysplastic lesions in the central nervous system is not, however, understood.

Compiling a description of extratemporal neocortical lesions encountered among surgical resection specimens obtained in the course of treating epilepsy represents an important starting point for understanding the potential neurobiologic significance and impact of these lesions on brain function. Making use of this material for mechanistic studies aimed at understanding seizures represents the next logical step in this analysis.

References

1. Engel J Jr, ed. Surgical Treatment of the Epilepsies. 2nd ed. New York, NY: Raven Press; 1993.

2. Engel J Jr. Surgery for seizures. N Engl J Med. 1996;334:647-652.

3. Wallace S, ed. Epilepsy in Children. London, England: Chapman & Hall Medical; 1996.

4. Tuxhorn I, Holthausen H, Boenigk H, eds. Paediatric Epilepsy Syndromes and Their Surgical Treatment. London, England: John Libbey; 1997.

5. Frater JL, Prayson RA, Morris HH III, Bingaman WE. Surgical pathology of extratemporal-based intractable epilepsy: a study of 133 consecutive resections. Arch Pathol Cab Med. 2000;124:545-549.

6. Mischel PS, Nguyen LP, Vinters HV. Cerebral cortical dysplasia associated with pediatric epilepsy: review of neuropathologic features and proposal for a grading system. l Neuropathol Exp Neurol. 1995; 54:137-153.

7. Rorke LB. Anatomical features of the developing brain implicated in pathogenesis of hypoxicischemic injury. Brain Pathol. 1992;2:211-221.

8. Towbin A. Brain Damage in the Newborn and its Neurological Sequels. Danvers, Mass: PRM Publishing; 1998.

9. Ellison D, Love S, Chimelli L, et al. Neuropathology: A Reference Text of CNS Pathology. London, England: Mosby; 1998:2.1-2.24.

10. Vinters HV, Farrell MA, Mischel PS, Anders KH. Diagnostic Neuropathology. New York, NY: Marcel Dekker; 432-452.

11. Hyman BT, Gomez-Isla T, Irizarry MC. Stereology: a practical primer for neuropathology. J Neuropathol Exp Neurol. 1998;57:305-310.

12. Coggeshall RE, Lekan HA. Methods for determining numbers of cells and synapses: a case for

more uniform standards of review. J Comp Neurol. 1996;364:6-15.

13. Farrell MA, DeRosa MJ, Curran JG, et al. Neuropathologic findings in cortical resections (including hemispherectomies) performed for the treatment of intractable childhood epilepsy. Acta Neuropathol 1992;83:246-259.

14. Vinters HV, Fisher RS, Cornford ME, et al. Morphological substrates of infantile spasms: studies based on surgically resected cerebral tissue. Childs New Syst. 1992;8:8-17.

15. Vinters HV, De Rosa MJ, Farrell MA. Neuropathologic study of resected cerebral tissue from patients with infantile spasms. Epilepsia. 1993;34:772779.

16. Peacock WJ, Wehby-Grant MC, Shields WD, et al. Hemispherectomy for intractable seizures in children: a report of 58 cases. Childs New Syst. 1996;12:376-384.

17. Mathern GW, Giza CC, Yudovin S, et al. Postoperative seizure control and antiepileptic drug use in pediatric epilepsy surgery patients: the UCLA experience, 1986-1997. Epilepsia. 1999;40:17401749.

18. Vinters HV, Kerfoot C, Catania M, Emelin JK, Roper SN, DeClue JE. Tuberous sclerosis-related gene expression in normal and dysplastic brain. Epilepsy Res. 1998;32:12-23.

19. Ying Z, Babb TL, Comair YG, Bingaman W, Bushey M, Touhalisky K. Induced expression of NMDAR2 proteins and differential expression of NMDAR7 splice variants in dysplastic neurons of human epileptic neocortex. / Neuropathol Exp Neurol. 1998;57:47-62.

20. Garbelli R, Munari C, De Biasi S, et al. Taylor's cortical dysplasia: a confocal and ultrastructural immunohistochemical study. Brain Pathol. 1999;9: 445-461.

21. Kerfoot C, Vinters HV, Mathern GW. Cerebral cortical dysplasia: giant neurons show potential for increased excitation and axonal plasticity. Dev Neurosci. 1999;21:260-270.

22. DeRosa MJ, Secor DL, Barsom M, Fisher RS, Vinters HV. Neuropathologic findings in surgically treated hemi-megalencephaly: immunohistochemical, morphometric and ultrastructural study. Acta Neuropathol. 1992;84:250-260.

23. Duong T, DeRosa MJ, Poukens V, Vinters HV, Fisher RS. Neuronal cytoskeletal abnormalities in human cerebral cortical dysplasia. Acta Neuropathol. 1994;87:493-503.

24. Richardson EP Jr. Pathology of tuberous sclerosis: neuropathologic aspects. Ann N Y Acad Sci. 1991;615:128-139.

25. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305-1315.

26. van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277: SOS-808.

27. Menchine M, Emelin JK, Mischel PS, et al. Tissue and cell-type specific expression of the tuberous sclerosis gene, TSC2, in human tissues. Mod Pathol. 1996;9:1071-1080.

28. Kerfoot C, Wienecke R, Menchine M, et al. Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesions of patients with tuberous sclerosis. Brain Pathol. 1996;6:367-377.

29. Johnson MW, Emelin JK, Park S-H, Vinters HV. Co-localization of TSC1 and TSC2 gene products in tubers of patients with tuberous sclerosis. Brain Pathol. 1999;9:45-54.

30. Vinters HV, Park SH, Johnson MW, Mischel PS, Catania M, Kerfoot C. Cortical dysplasia, genetic abnormalities and neurocutaneous syndromes. Dev Neurosci. 1999;21:248-259.

Harry V. Vinters, MD

Accepted for publication January 31, 2000.

From the Departments of Pathology & Laboratory Medicine and Neurology, University of California, Los Angeles.

Reprints: Harry V. Vinters, MD, UCLA Medical Center, CHS 18-170, Los Angeles, CA 90095-1732.

Copyright College of American Pathologists Aug 2000
Provided by ProQuest Information and Learning Company. All rights Reserved